NUS Links:
Summary
The combination of chemotherapy (or targeted therapy) with immunotherapy is emerging rapidly as a promising strategy in the first line treatment against several tumor types. This study led by Dr Raghav Sundar provides the basis to further optimise treatment options for first-line metastatic GEAC patients using combination of Immunotherapy and chemotherapy.
Link to article: https://bit.ly/35WzvHy
CIITA is the master regulator of MHC class-II immune genes that are important for defense mechanism against infections and cancer …
Chemotherapy, although the first line of defense in cancer treatment, is indiscriminate and is damaging to the entire body, which, …
This research, led by N2CR members Prof Goh Boon Cher and Prof Shazib Pervaiz with Dr Jayshree Hirpara as the …